Company intelligence / Profile preview

Shanghai Bovax Biotechnology Co., Ltd.

Shanghai, Shanghai, Chinam.bovaxbio.com ↗

Ownership: Private
Employees: ~80
Development stage: Phase 1

Overview

The company has multiple HPV vaccines in clinical development. The 9-valent HPV vaccine is in Phase III clinical trials (first of its kind to enter Phase III in China), the 4-valent HPV vaccine has completed Phase III trials, the 15-valent HPV vaccine has been approved for clinical trials, and the recombinant EV71 vaccine is in Phase I clinical stage.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Recombinant protein vaccinesRecombinant protein drugsVirus-Like Particles (VLPs)
Industry: Biotech

Drug pipeline

13 assets

15-valent human papillomavirus recombinant vaccine

12 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Shanghai Bovax Biotechnology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Bovax Biotechnology Co., Ltd..

Explore the full profile